TBRU Summary for teh Gates Meeting tomorrow

Extracted statements

Rule-extracted, not adjudicated. The grade says what may be done with each one; read the document above before relying on any of them.

In context

A single line often inverts meaning once you see what it answers, so neighbouring messages are always shown.

1. 2018-09-20 15:29 Alison Kraigsley
   Dear Alan and Katrin, I've put together a brief summary from the TBRUs. The attached document includes the 4 responses from the individual TBRUs imbedded in the word files. There's a summary of the TBRU awards, their grant numbers, and project expiration dates. There's also a high-level summary of some metrics (# publications, # trainees, # funded spin-off grants). Page 2 has a summary of some of the vaccine-related work being done by the TBRUs. Page 3 has a bulleted summary of work being done that can be categorized into drugs and diagnostics. Page 4 describes some of the work being done to refine animal models. Also attached is the one-page slide describing all 4 TBRUs. ASTRa is the more vaccine relevant TBRU. Since Katrin will be in the room, I think you'll be well-covered. Please let me know if you have any questions or if there is anything additional needed. Best regards, Alison Alison Kraigsley, Ph.D. Program Officer NIH/NIAID/DMID/RDB @nih.gov Office: Mobile: TBRU Summary September 20, 2018 Below you will find a compiled summary of the information provided by the 4 TBRU centers. Here are the original files: Center Name PIs Grant Number Accomplishment File Expires ASTRa Henry Blumberg Joel Ernst AI111211 2018 TBRU Annual Meeting_Pre7/31/2021 CLEAR-TB Jerry Ellner David Alland Padmini Salgame AI111276 2018 TBRU Updates and 7/31/2021 LIMAA Branch Moody Megan Murray AI111224 TBRU LIMAA 2018 PI survey.docx 01/31/2022 Tri-I Carl Nathan Mike Glickman AI111143 2018 Tri- I TBRU Updates and 6/30/2021 • TBRUs were awarded in 2014 and run until 2021 (LIMAA continues until Feb 2022) • Total value over 7 years: ~$105M (~$15M/year for 7 years) • Annual cross-collaborative supplement program supports cross-collaborative projects, many led by early career investigators (Projects are ~$200K each/year/center) High-Level Data as of 9/17/2018. Grant years completed: 4; Grant years remaining: 3 • Number of Publications = 144 I. there may be redundant publications in the list if the same publication was listed under two centers II. this number includes both reviews as well as research publications • Number of Trainees = 87 o Number of trainees seeking TB-related independent careers = 33 I. Defined: new faculty position, on the job market, late post-docs • Number of Spin-Off Grants FUDNED = 43 o Number of funded spin-off grants for NI/ESI = 18 o Number of grants waiting review or funding decision: 7 o Funders of spin-off grants: NIH, DoD, Gates, Foundations, etc. • Number of projects in translational categories for all 4 centers o Vaccines: 7 o Drugs: 15 o Diagnostics: 5 o Animal Models: 7 I. These numbers aren't reflective of the full spectrum of work being conducted by the TBRU Network, just an overview summary II. While the TBRU Network has a focus on Paucibacillary disease, there are a number of projects in the translational space : VACCINES wu) TBRU Summary September 20, 2018 Research Highlights: VACCINES • Development and Publication of a Novel Response Spectrum Assay (RSA). [ASTRa] The 60-Mtb antigen "Response Spectrum Assay (RSA)" performed on whole blood has been developed by the TBRU-ASTRa team and validated in Emory Vaccine Center laboratories. Assay development and optimization of the a 7-day diluted whole blood assay to measure antigen-specific T cell responses was of this novel assay was recently published in The Journal of Immunology (J Immunol 2018; 200(8):3008-3019) with Cheryl Day (co-PD of Project 1) as the senior author. Interim data analysis from a cohort of patients with latent TB infection (LTBI) that accepted treatment at the DeKalb County Board of Health were presented at NIAID at the TBRU-Network

Full conversation →